RecruitingPhase 2NCT05842512

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of ADI-PEG 20 or Placebo in Subjects With Nonalcoholic Steatohepatitis (NASH)

Sponsor

Polaris Group

Enrollment

60 participants

Start Date

Sep 13, 2023

Study Type

INTERVENTIONAL

Conditions

Nonalcoholic Steatohepatitis (NASH)

Summary

Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ADI-PEG20 and Placebo for people with nonalcoholic steatohepatitis (nash). The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGADI-PEG20

Treatment for NASH

OTHERPlacebo

Treatment for NASH

Locations(10)

Ditmanson Medical Foundation Chiayi Christian Hospital；Chiayi Christian Hospital (CYCH)

Chiayi City, Taiwan, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital(KMUH)

Kaohsiung, Taiwan, Taiwan

E-Da Hospital (EDH)

Kaohsiung, Taiwan, Taiwan

Chang Gung Medical Foundation-Kaohsiung (CGMF-KS)

Kaohsiung, Taiwan, Taiwan

Chang Gung Medical Foundation-Keelung (CGMF-KL)

Keelung, Taiwan, Taiwan

National Cheng Kung University Hospital (NCKUH)

Tainan, Taiwan, Taiwan

National Taiwan University Hospital (NTUH)

Taipei, Taiwan, Taiwan

Taipei Veterans General Hospital (TPVGH)

Taipei, Taiwan, Taiwan

Fu Jen Catholic University Hospital (FJCUH)

Taipei, Taiwan, Taiwan

Chang Gung Medical Foundation-Linkou (CGMF-LK)

Taoyuan, Taiwan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05842512

Related Trials

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT075536631 location

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT069473041 location

To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects

NCT062160411 location

Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis

NCT035724651 location